Flourescence Spectroscopy Used to Detect CAD
November 19, 2007 – Prescient Medical Inc. has acquired Time Resolved Light Induced Fluorescence Spectroscopy (TR-LIFS) technology designed for early detection, diagnosis and quantification of coronary artery disease.
TR-LIFS exploits the phenomenon that bi-products of metabolic activity behave differently than surrounding tissue. In TR-LIFS, a short light pulse (picoseconds) is used to excite the tissue, and then the resulting light that emanates from the tissue is monitored over a brief time span (several nanoseconds).
The company expects the technology to be used to identify coronary plaques before a major heart attack can occur. TR-LIFS is reportedly well suited to detecting macrophages, and Prescient Medical plans to integrate TR-LIFS technology into its vPredict Optical Catheter System, an intravascular diagnostic instrument that is currently in development.
For more information: www.prescientmedical.com
More like this
- New Technology From Prescient Medical Featured at Canaccord Adams Cardiovascular Conference
- New Methods to Detect Vulnerable Plaque
- Findings for Vulnerable Plaque Treatment Alternative to be Featured at TCT
- Prescient Medical Receives Frost & Sullivan Innovation of the Year Award for Vulnerable Plaque Stent, Imaging System
- Fluorescent Laser Used to Detect Colon Cancer